{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T20:23:27Z","timestamp":1788639807516,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clgc.2024.102123","type":"journal-article","created":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T18:14:15Z","timestamp":1716488055000},"page":"102123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Dual mTOR1\/2 Inhibitor Sapanisertib (FTH-003\/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2328-3421","authenticated-orcid":false,"given":"Joaquim","family":"Bellmunt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Maroto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Bonfill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Perez-Gracia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Juanpere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8233-1035","authenticated-orcid":false,"given":"Anna","family":"Hernandez-Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Hernandez-Llodra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1301-2599","authenticated-orcid":false,"given":"Ana","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7772-9030","authenticated-orcid":false,"given":"Oscar","family":"Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejo","family":"Rodriguez-Vida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clgc.2024.102123_bib0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.clgc.2024.102123_bib0002","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up \u2606","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.clgc.2024.102123_bib0003","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clgc.2024.102123_bib0004","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102123_bib0005","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.clgc.2024.102123_bib0006","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","author":"Massard","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10122","key":"10.1016\/j.clgc.2024.102123_bib0007","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.clgc.2024.102123_bib0008","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.clgc.2024.102123_bib0009","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"issue":"7492","key":"10.1016\/j.clgc.2024.102123_bib0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Weinstein","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.clgc.2024.102123_bib0011","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2024.102123_bib0012","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1158\/1078-0432.CCR-13-2506","article-title":"Phase i study of oral rigosertib (ON 01910.NA), a dual inhibitor of the PI3K and PLK1 pathways, in adult patients with advanced solid malignancies","volume":"20","author":"Bowles","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2024.102123_bib0013","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/bjc.2013.474","article-title":"A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours","volume":"109","author":"Bowles","year":"2013","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2024.102123_bib0014","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.hoc.2012.02.014","article-title":"MTOR signaling pathway and mTOR inhibitors in cancer therapy","volume":"26","author":"Gomez-Pinillos","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clgc.2024.102123_bib0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.1226344","article-title":"Genome sequencing identifies a basis for everolimus sensitivity","volume":"338","author":"Iyer","year":"2012","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.clgc.2024.102123_bib0016","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1093\/annonc\/mds057","article-title":"Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers","volume":"23","author":"Seront","year":"2012","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.clgc.2024.102123_bib0017","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1002\/cncr.33071","article-title":"A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma","volume":"126","author":"McPherson","year":"2020","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clgc.2024.102123_bib0018","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O'Reilly","year":"2006","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.clgc.2024.102123_bib0019","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3892\/mmr.2015.4528","article-title":"PP242 suppresses bladder cancer cell proliferation and migration through deactivating the mammalian target of rapamycin complex 2\/AKT1 signaling pathway","volume":"13","author":"Zhang","year":"2016","journal-title":"Mol Med Rep"},{"issue":"8","key":"10.1016\/j.clgc.2024.102123_bib0020","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/1535-7163.MCT-10-1099","article-title":"Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin","volume":"10","author":"Bhagwat","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"10.1016\/j.clgc.2024.102123_bib0021","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1158\/1541-7786.MCR-18-0923","article-title":"Novel oral mTORC1\/2 inhibitor TAK-228 has synergistic antitumor effects when combined with paclitaxel or PI3Ka inhibitor TAK-117 in preclinical bladder cancer models","volume":"17","author":"Hern\u00e1ndez-Prat","year":"2019","journal-title":"Mol Cancer Res"},{"issue":"15_suppl","key":"10.1016\/j.clgc.2024.102123_bib0022","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.9607","article-title":"Phase II study of TAK228 in patients with advanced non-small cell lung cancer (NSCLC) harboring NFE2L2 and KEAP1 mutations","volume":"38","author":"Paik","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102123_bib0023","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jtho.2022.09.225","article-title":"Targeting NFE2L2\/KEAP1 mutations in advanced NSCLC with the TORC1\/2 inhibitor TAK-228","volume":"18","author":"Paik","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2024.102123_bib0024","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR project genie: Powering precision medicine through an international consortium","volume":"7","author":"Sweeney","year":"2017","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.clgc.2024.102123_bib0025","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.juro.2015.06.115","article-title":"Second line chemotherapy for advanced and metastatic urothelial carcinoma: vinflunine and beyond\u2014a comprehensive review of the current literature","volume":"195","author":"Oing","year":"2016","journal-title":"J Urol"},{"issue":"27","key":"10.1016\/j.clgc.2024.102123_bib0026","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","article-title":"Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract","volume":"27","author":"Bellmunt","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102123_bib0027","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/annonc\/mdt007","article-title":"Long-term survival results of a randomized phase iii trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy","volume":"24","author":"Bellmunt","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102123_bib0028","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1200\/JCO.1997.15.5.1853","article-title":"Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma","volume":"15","author":"McCaffrey","year":"1997","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clgc.2024.102123_bib0029","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1038\/s41416-020-01041-x","article-title":"Phase 1 study of mTORC1\/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer","volume":"123","author":"Voss","year":"2020","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2024.102123_bib0030","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1159\/000376551","article-title":"Second-line treatment of advanced urothelial cancer with paclitaxel and everolimus in a german phase II trial (AUO trial AB 35\/09)","volume":"89","author":"Niegisch","year":"2015","journal-title":"Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102123_bib0031","doi-asserted-by":"crossref","first-page":"E432","DOI":"10.1093\/oncolo\/oyab075","article-title":"Phase II clinical andtranslational study of everolimus \u00b1 paclitaxel as first-linetherapy in cisplatin-ineligible advanced urothelial carcinoma","volume":"27","author":"Jun","year":"2022","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.clgc.2024.102123_bib0032","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41591-021-01317-6","article-title":"An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer","volume":"27","author":"Powles","year":"2021","journal-title":"Nat Med"},{"issue":"49","key":"10.1016\/j.clgc.2024.102123_bib0033","doi-asserted-by":"crossref","first-page":"25476","DOI":"10.1074\/jbc.M116.760249","article-title":"Nrf2 transcription factor can directly regulate mTOR: Linking cytoprotective gene expression to a major metabolic regulator that generates redox activity","volume":"291","author":"Bendavit","year":"2016","journal-title":"J Biol Chem"},{"issue":"22","key":"10.1016\/j.clgc.2024.102123_bib0034","doi-asserted-by":"crossref","first-page":"9095","DOI":"10.1158\/0008-5472.CAN-10-0384","article-title":"Global downstream pathway analysis reveals a dependence of oncogenic NF-E2: related factor 2 mutation on the mTOR growth signaling pathway","volume":"70","author":"Shibata","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2024.102123_bib0035","doi-asserted-by":"crossref","unstructured":"Jin J, Rohatgi A, Gabrielle A, et al. Interim results from a phase I\/II study of duvelisib PI3K\u03b4\u03b3 inhibitor and nivolumab in patients with advanced unresectable melanoma who have progressed on anti-PD1 therapy. 2023;41(16_suppl):9540. 10.1200\/JCO.2023.41.16_SUPPL.9540","DOI":"10.1200\/JCO.2023.41.16_suppl.9540"},{"key":"10.1016\/j.clgc.2024.102123_bib0036","doi-asserted-by":"crossref","unstructured":"Tawbi HA-H, Peng W, Phillips S, et al. Safety results from phase I\/II study of the PI3K\u03b2 inhibitor GSK2636771 (G) in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss. 2020;38(15_suppl):e22000. 10.1200\/JCO.2020.38.15_SUPPL.E22000.","DOI":"10.1200\/JCO.2020.38.15_suppl.e22000"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T01:56:46Z","timestamp":1738547806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324000946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1558767324000946"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102123","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual mTOR1\/2 Inhibitor Sapanisertib (FTH-003\/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102123","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102123"}}